Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > New all time low at 0.04 cad?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(77)
•••
Comment by Pareto8020on Jul 03, 2024 7:21pm
106 Views
Post# 36117336

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New all time low at 0.04 cad?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New all time low at 0.04 cad?Anyone recall the PRC breakdown that appeared to use Sirona fonts and graphics so one could infer it was a way for the company to promote themselves via a third party?

https://57ea05b9-8ae7-4fa0-b2d8-87d70d135d8c.usrfiles.com/ugd/57ea05_4dfabf8ca3aa4f9e929d16bcfcc954dd.pdf  

Some of the highlights seem humorous now that a couple years have shot by:

"We estimate that AbbVie will take around 10% of the $8B USD skin-lightening market, which equates to an estimated $40M USD in annual royalty payments for Sirona Biochem. $680M USD in total over 17 years."

"AbbVie is already in the advanced stages of its development and commercialization process for TFC-1067. While we agree with the assessment that it might still take a few months for the company to be ready to release a commercial product based on the compound, we can’t stress enough the potential impact of that product and the revenue it would generate for Sirona Biochem through royalty payments."
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities